Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Hyperuricemia may contribute to disease progression in autosomal dominant polycystic kidney disease (ADPKD), but its prognostic impact remains unclear, especially across sex and age groups. Given the need for individualized care, we investigated the association between hyperuricemia and kidney prognosis using an attribute-based cross-classification approach by sex and age.
We analyzed 553 ADPKD patients not undergoing renal replacement therapy (median age, 43 years; mean eGFR, 55.9 mL/min/1.73 m²; median total kidney volume, 1335.4 mL). Hyperuricemia was defined as serum urate ≥7.0 mg/dL or treatment with urate-lowering drugs. Patients were cross-classified by sex (men/women) and age (<50/≥50 years). The renal outcome—defined as ≥30% decline in eGFR or initiation of renal replacement therapy—was assessed using Cox regression models. Interaction terms between hyperuricemia and age ≥50 years were tested. The mean follow-up was 6.9 years, during which 266 patients experienced renal events.
Hyperuricemia was not associated with poorer renal prognosis in the overall cohort (HR=1.34, P=0.120). However, a significant interaction was observed between hyperuricemia and age ≥50 years in men (interaction P=0.004), but not in women (interaction P=0.450). Cross-classification analysis revealed that hyperuricemia was strongly associated with worse renal outcomes in younger patients, particularly women under 50 years of age (HR=3.51, P=0.034) and men under 50 (HR=2.06, P=0.026), while no significant associations were found in either sex aged ≥50 years. These findings indicate that the adverse renal impact of hyperuricemia is age-dependent and most pronounced among younger women.
Hyperuricemia is a modifiable risk factor for renal progression in ADPKD, especially in younger individuals, with the greatest impact observed in younger female patients. Attribute-based cross-classification by sex and age provides novel insights into individualized risk stratification and highlights subgroups at higher risk of kidney function decline. Presented from the perspective of Preserving Kidney Health, this work extends prior findings and was previously presented at the American Society of Nephrology Kidney Week 2025 as an encore abstract.
